Ao-Kun Liu

Abstract Somatostatin receptor 3 (SSTR3) exerts critical biological functions such as negatively regulating hormone release and cell proliferation, making it a promising therapeutic target for endocrine disorders and nonfunctioning pituitary tumors. However, the development of more effective and safer somatostatinergic therapies is limited due to a lack of molecular understanding of the ligand recognition and conformational dynamics of SSTR3.